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After the publication of the 10-year survival data from Milan on the adjuvant use of the block sequential regimen consisting of
four cycles of adriamycin followed by eight cycles of intravenous CMF, many centres adopted this as standard of care for high
risk, multiple node-positive breast cancer. For this reason it was identiﬁed as the standard arm for the Anglo-Celtic adjuvant
high-dose chemotherapy trial. This study reports on the experience of this regimen in 329 women with early breast cancer
involving at least four axillary nodes, who were treated outside any adjuvant chemotherapy trial. At a median follow-up of 3
years, the overall 5-year disease-free survival is 61%, and the overall survival is 70%. These data conﬁrm the efﬁcacy of this
regimen in non-trial patients, and, for the same high risk subgroup, indicate that this approach offers an outcome at least as
good as that seen in the CALGB 9344 AC-Taxol arm, and the NCIC days 1 and 8 CEF.
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The place of anthracyclines in the adjuvant treatment of early
breast cancer has been established by a number of individual trials
in addition to recent overviews (Early Breast Cancer Trialists Colla-
borative Group, 1998; 2002). However, the optimal anthracycline
regimen remains less well deﬁned and opinions vary as to whether
women with early breast cancer gain most from several identical
cycles of chemotherapy, or sequential ‘blocks’ of different agents
or combinations of agents.
In the early 1980s, as a consequence of the theoretical modelling of
the Goldie–Coldman hypothesis (Goldie and Coldman, 1979; Gold-
ie et al, 1982), several clinical trials were established to determine if
alternating cycles of chemotherapy would be better at eradicating
sub-clones of resistant malignant cells than the sequence of several
cycles of one regimen followed by several of another, non-cross-resis-
tant combination. Gianni Bonadonna and co-workers initiated one
such study in Milan for women with multiple node-positive breast
cancer. The ﬁrst report from that study concluded that not only
was the theoretically better alternating regimen not superior, but it
was quite clearly inferior to the block sequential approach (Buzzoni
et al, 1991). A subsequent theoretical analysis sought to explain this
result (Norton and Day, 1992), and its validity was conﬁrmed with
the publication of the 10-year outcome data (Bonadonna et al,
1995). However, irrespective of the explanation, the success of this
regimen in this high risk group led it to be adopted in many
European and North American centres as standard of care for
women with four or more involved axillary nodes. It was also
adopted as the control arm of the Anglo-Celtic adjuvant high-dose
chemotherapy trial, expected to report for the ﬁrst time in 2002.
More recently, two other adjuvant breast cancer trials have
demonstrated a clear advantage of a newer regimen over an older
one. Firstly, the NCIC MA5 trial in which methotrexate was replaced
by epirubicin (Levine et al, 1995), and more recently, the CALGB
9344 study, which although reported in abstract form only to date,
suggests that the addition of a block of four doses of single agent taxol
may improve overall survival (Henderson et al, 1998).
This study is therefore an audit of the experience of the adriamy-
cin-CMF regimen in non-trial patients from several breast cancer
units, all participants in the Anglo-Celtic trial, in order to determine
how it compares to these two other pivotal adjuvant regimes.
METHODS
Patients
Ten centres participating in the Anglo-Celtic trial (eight in the UK,
one each in Ireland and New Zealand) agreed collectively to audit
the outcomes of those patients not enrolled into that trial, for
reasons of patient or clinician choice, but treated nonetheless with
the control arm used in the trial, the adriamycin-CMF regime. All
patients had to have had potentially curative loco-regional surgery
for their ﬁrst diagnosis of invasive breast cancer, and to have been
staged according to local practice as having breast cancer stages
II–IIIA only. Patients with locally advanced tumours were not
included. For the purposes of this audit, there were no exclusions
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the basis of other medical diagnoses. Patients included had been
treated with the adriamycin-CMF sequential regimen, having been
offered that by their treating physician on the basis of his/her own
assessment of their ﬁtness for this regimen.
The data were then supplied in an anonymised fashion to the
Edinburgh Breast Unit on request, and had therefore not been
subjected to any external data audit. The data were then combined,
and no analyses of the results in the individual centres have been
performed.
Statistics
Data were collected from the various centres and combined.
Patients treated with this same regimen with less than four
conﬁrmed involved axillary nodes were not included. Disease-free
and overall survival data were calculated from date of ﬁrst
chemotherapy administration, and analysed using the Kaplan–
Meier method. Data on dose reductions and/or dose delays were
provided by the centres, but were missing for just over one third
of the patients. Analyses on dose delivery have therefore been
conﬁned to the 64% of patients for whom data were available.
No data on the actual number of days’ delay were available, and
so true dose intensity cannot be calculated. It has been estimated
using the percentage of planned dose actually delivered for the
majority of patients for whom data were available:
Mean % given dose 
P
% planned dose given for each patient
Number of patients with available data
Treatment
This consisted of four cycles of single agent doxorubicin (adriamy-
cin) 75 mg m
72, given as an i.v. bolus once every 3 weeks,
followed by eight cycles of cyclophosphamide 600 mg m
72, meth-
otrexate 40 mg m
72 and 5-ﬂuorouracil 600 mg m
72, all given as
i.v. bolus once every 3 weeks. Decisions about dose modiﬁcation
and/or treatment delay were left to the discretion of the local prac-
tice. Radiotherapy was given as per local practice. All women with
Oestrogen (ER) and/or Progesterone (PgR) positive breast cancer
were to receive tamoxifen (or equivalent) for 5 years.
RESULTS
Patients
A total of 329 patients were identiﬁed who had been treated with
the adriamycin-CMF regimen outside a clinical trial, and known to
have at least four involved ipsilateral axillary nodes. The median
number of involved nodes was eight, with a range of 4–36. The
median age of the patients was 49 years, but with a wide range
from 26 to 73 years.
Tumours
Median size of the tumours was 28 mm, ranging from 6 to
200 mm. Grade was assessed by the modiﬁed Bloom Richardson
method, and results were available in 300 women, of whom 167
(56%) had grade 3 tumours. One patient had bilateral cancers,
and there were almost exactly equal proportions of right and left
sided breast cancers (49% and 51% respectively). The majority of
tumours were ER+ve (see Table 1 for details).
Treatment
The majority of women received all the planned chemotherapy (see
Table 2). Data on the details of treatment delivery are missing in
36% of patients, but of those for whom data are available, 43%
of patients received every cycle exactly on time, and in 78% of
patients (95% of cycles), treatment was at full dose. This resulted
in the mean dose delivery for both adriamycin and CMF of over
90% (see Table 2). Even when including the patients with missing
data, a minimum of 51% and 50% respectively of patients received
100% of the planned dose of adriamycin and CMF dose. For the
vast majority of patients this was achieved without the use of G-
CSF, which was not used in at least 224 patients, with only eight
patients known to have received it.
Radiotherapy was given to 88% of patients, although a break-
down by the extent of loco-regional surgery is not available.
Tamoxifen was recorded as given to over 90% of patients with
ER +ve tumours, and almost one-third (31%) of women with
ER 7ve tumours.
Outcome
The overall survival for the whole cohort is shown in Figure 1,
where it can be seen that the actuarial 5-year survival is 70%.
Figure 2 shows the disease-free survival, which is 61% at 5 years.
These data are shown separately for those women with 4–9 nodes
and 10+ nodes respectively in Figures 3 and 4. It should be noted
that the 5-year disease-free and overall survival has not yet been
reached for those women with between four and nine involved
axillary nodes, whereas the ﬁgures are respectively 4 and 5.47 years
for those women with at least 10 involved axillary nodes.
For the 33 (10%) of women who did not complete all 12 cycles
of chemotherapy, there was no evidence of a poorer survival (data
not shown), apart from the eight for whom treatment was stopped
because of a recurrence of breast cancer during their adjuvant
therapy.
Furthermore there is no evidence of a failure to deliver this ther-
apy to older women, nor any suggestion that their outcome is
poorer as compared with younger women in the audit. It is clear
from Table 3 that although there was a trend towards omitting
more cycles in the older patients, this did not translate into an
overall lower mean dose delivery or a poorer survival. The median
survival has not been reached in any age group (under 40, 40–50,
50–60 or over 60 years ) with no evidence of differential survival
by age (P40.4 for any comparison) (data not shown).
Table 4 shows these ﬁgures and the available outcome data for
patients with four or more involved nodes in both the NCIC
MA5 study and the CALGB 9344. It can be seen that patients in
this audit of routine practice do not appear to have a survival
any poorer than the women in either the CEF or AC-Taxol arms
of these two North American randomised trials.
DISCUSSION
This audit was performed to determine the efﬁcacy of the block
sequential adriamycin-CMF regimen in non-trial patients. It is
clearly an effective regimen, and although the patients are by deﬁ-
nition a more heterogeneous group than those entered into clinical
trials, the outcome data observed compare very favourably with the
5-year data seen in the original report of this regimen from the
Institute Tumori di Milano. Indeed the fact that the outcomes
appear even better than in that original report, as well as the 10-
year data, may be due to the use of tamoxifen in almost all women
with ER positive tumours in this series of patients, whereas it was
not mandated in the original study. Another difference between
these data and the original report is the outcome for the older
woman: in the original Milan experience it is clear that the post-
menopausal women fared worse, whereas in this audit there is
no evidence of a poorer outcome. However, imbalances in other
prognostic factors could have contributed to these differences in
outcome from that earlier report. Whatever the reason, the most
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there has been no loss of efﬁcacy for this regimen. This is an
unusual occurrence in oncology, with the much more common
pattern being less efﬁcacy seen outside of a pivotal clinical trial.
The audit also demonstrated that this regimen is deliverable to
the majority of patients despite involving 36 weeks’ chemotherapy.
Assessing toxicity is difﬁcult in this type of retrospective audit, but
there were no reports of toxic deaths or major morbidity. Further-
more, the small number of patients who failed to complete all the
planned therapy, and the high mean dose delivered are further
testimony to the applicability of this treatment in routine practice.
Having thus demonstrated that this regimen can be delivered
outside clinical trials without any apparent loss of efﬁcacy, its place
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Table 1 Patient and tumour details
Median Range
Age 49 years 26–73
Tumour size 28 mm 6–200 mm
Number of lymph nodes found 8 4–36
% of all patients
4–9 nodes 57%
10+ nodes 43%
Grade 1 20/300 (7%)
Grade 2 113/300 (38%)
Grade 3 167/300 (56%)
ER +ve 165/257 (64%)
Left sided cancer 160/315 (51%)
Table 2 Received treatment
Mean % of Mean %
planned cycles given dose
Adriamycin
a 97.7 91
CMF
a 97.4 92
ER +ve tumours ER 7ve tumours
Tamoxifen 92% 31%
All cycles (%)
Cycles omitted
a 3
Cycles dose reduced
a 5
Cycles delayed
a 12
All patients (%)
Radiotherapy 88
aData on actual doses given not available in 118 (36%) of patients. 1.0
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Figure 1 Overall survival for all patients with 4+ nodes.
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Figure 2 Disease-free survival for all patients with 4+ nodes. 1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
P
r
o
b
a
b
i
l
i
t
y
0          1          2          3          4          5          6          7          8
Years
4–9 nodes
10+ nodes
Figure 3 Overall survival by number of involved nodes.
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Figure 4 Disease-free survival by number of involved nodes.
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recently been reported to be superior to previous standards of care.
A criticism of the adriamycin-CMF regimen is that it has never
been compared with classical CMF. This omission will in large part
be addressed by two parallel UK randomised trials which have
compared CMF with a regimen consisting of four cycles of single
agent epirubicin followed by four of CMF. The results of these
two trials are awaited, although it has to be admitted that in these
two studies, the CMF was given for four rather than eight cycles,
and adriamycin was substituted by the less cardiotoxic agent epir-
ubicin. Indirect comparisons can be made with data from other
studies, although such analyses must be interpreted with caution
and are in effect hypothesis generating rather than conﬁrmatory.
Firstly, the NCIC MA5 trial in which methotrexate was substi-
tuted by epirubicin in six cycles of classical CMF convincingly
showed that the use of anthracyclines can further improve the
outlook for women with node positive breast cancer. Data on
the 4+ node group are not available from the original publication,
but have been made kindly available by the company that
supported the study (Pharmacia). It can be seen in Table 4 that
not only is the adriamycin-CMF regimen clearly superior to the
classical CMF control arm, but could even be better than the
CEF arm! The second data set with which a comparison can be
made is the CALGB 9344 trial, in which a double randomisation
occurred, between three different doses of adriamycin within four
cycles of AC, and then to either four cycles of taxol or no further
chemotherapy. The data have been presented on several occasions,
but as yet no peer-reviewed publication has appeared. Therefore
the data on the 4–9 and 10+ node subgroups are only available
from a pharmaceutical company publication. It can again be seen
in Table 4 that the outcome of patients in this audit is superior
to the control arm of AC, and apparently equivalent to AC
followed by taxol. Given that AC has been shown to be equivalent
to classical CMF in both node negative and node positive patients,
this further substantiates the view that adriamycin-CMF is superior
to four cycles of AC or six cycles of CMF, and appears to be at
least as effective as either AC-Taxol or days 1 and 8 CEF.
This audit has clearly demonstrated the efﬁcacy outwith clinical
trials of the sequential adriamycin-CMF regimen for women with
high risk early breast cancer. Furthermore, indirect comparisons
with the outcome data for two other regimens when given to this
same high risk group show no evidence that they are superior. The
results of the Anglo-Celtic I trial which compared the sequential
adriamycin-CMF regimen with a myeloablative treatment are
awaited, but unless that trial is positive (which would somewhat
go against the trend of other recently reported high dose trials),
then the adriamycin-CMF regimen would appear to be deliverable
in routine practice, with as good an outcome as any other regimen.
Two other studies of adjuvant chemotherapy in high risk
women have been published recently. One, the small Dutch high
dose trial, did not deﬁne risk by the number of pathological nodes
involved, and so comparisons with the current data set are difﬁcult
(Rodenhuis et al, 1998). The other, the interesting Swedish study of
‘tailored’ FEC against high dose chemotherapy, deﬁned risk by the
anticipated 5 year outcome with standard therapy (Bergh et al,
2000). This translated into including women without low-grade
tumours, and either eight or more nodes when the tumour was
ER positive or ﬁve or more nodes when it was ER negative. The
outcome data for this study have been estimated from the
published survival curves, and given that the patients in the
Swedish study were at a slightly higher risk than the 4+ criterion
for this study, the outcomes are again reasonably comparable.
We conclude that appropriately sequenced anthracycline based
polychemotherapy is a standard of care for high risk breast cancer
that, from indirect comparisons, has not been improved upon by
the addition of taxanes or by escalation of dose. It remains to be
seen whether the sequenced anthracycline regimen can be bettered
with a different taxane, such as docetaxol, or by ‘tailoring’ the
regimen to either the patients’ tolerability or an approach using
markers of drug sensitivity which have been derived from an
individual’s tumour biology.
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